|
|
| (32 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | {| style="border: 0px; font-size: 85%; margin: 3px; width:600px;" align=center |
| {{Fondaparinux}}
| | |valign=top| |
| {{CMG}}; {{AE}} {{AZ}}
| | |+ |
| '''''For patient information, click <u>[[Fondaparinux (patient information)|here]]'''''</u>.
| | ! style="background: #4479BA; color:#FFF; width: 100px;" | |
| {{SB}} Arixtra<sup>®</sup>
| | ! style="background: #4479BA; color:#FFF; width: 200px;" | |
| | | ! style="background: #4479BA; color:#FFF; width: 250px;" | |
| ==Overview==
| | |- |
| '''Fondaparinux''' (trade name '''Arixtra''') is an [[anticoagulant]] medication chemically related to [[low molecular weight heparin]]s. It is marketed by [[GlaxoSmithKline]]. A generic version developed by Alchemia is marketed within the US by [[Dr. Reddy's Laboratories]].
| | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | |
| | | | style="padding: 5px 5px; background: #F5F5F5;" | |
| ==Category==
| | | style="padding: 5px 5px; background: #F5F5F5;" | |
| [[Factor Xa]] inhibitors.
| | |} |
| | |
| ==FDA Package Insert==
| |
| ===Arixtra<sup>®</sup>===
| |
| '''| [[Fondaparinux indications and usage|Indications and Usage]]'''
| |
| '''| [[Fondaparinux dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Fondaparinux dosage forms and strengths|Dosage Forms and Strengths]]'''
| |
| '''| [[Fondaparinux contraindications|Contraindications]]'''
| |
| '''| [[Fondaparinux warnings|Warnings and Precautions]]'''
| |
| '''| [[Fondaparinux adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Fondaparinux drug interactions|Drug Interactions]]'''
| |
| '''| [[Fondaparinux use in specific populations|Use in Specific Populations]]'''
| |
| '''| [[Fondaparinux overdosage|Overdosage]]'''
| |
| '''| [[Fondaparinux description|Description]]'''
| |
| '''| [[Fondaparinux clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Fondaparinux nonclinical toxicology|Nonclinical Toxicology]]'''
| |
| '''| [[Fondaparinux clinical studies|Clinical Studies]]'''
| |
| '''| [[Fondaparinux how supplied storage and handling|How Supplied/Storage and Handling]]'''
| |
| '''| [[Fondaparinux patient counseling information|Patient Counseling Information]]'''
| |
| '''| [[Fondaparinux labels and packages|Labels and Packages]]'''
| |
| | |
| [[image:fond.png]]
| |
| | |
| ==Mechanism of Action==
| |
| The antithrombotic activity of fondaparinux sodium is the result of [[antithrombin]] III (ATIII)-mediated selective inhibition of [[Factor Xa]]. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits [[thrombin ]]formation and thrombus development.
| |
| | |
| Fondaparinux sodium does not inactivate thrombin (activated Factor II) and has no known effect on platelet function. At the recommended dose, fondaparinux sodium does not affect[[ fibrinolytic ]]activity or bleeding time.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| ==References== | |
| | |
| {{Reflist|2}}
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |